| abstract |
In order to provide an antibody that can detect a target molecules useful for cancer treatment or the like and that can specifically bind to said molecules, and an anti-cancer agent that uses said antibody as an active component, a comparison between prostate cancer cell lines (between LNCaP-CR cells and LNCaP cells) was carried out using SST-REX, and CXADR was identified as a molecule that is involved in tumorigenicity and the like. Furthermore, monoclonal antibodies against CXADR were produced, and because the monoclonal antibodies were found to exhibit anti-cancer activity, ADCC activity, CDC activity and the like, it was discovered that the antibody that binds to the epitope present at position 181-230 on human-derived CXADR protein exhibits an anti-cancer effect against prostate cancer cells, pancreatic cancer cells and colorectal cancer cells. It was also demonstrated that said antibody has ADCC activity and CDC activity. The structure of the variable region of the heavy and light chains of the antibody was successfully determined. |